ERCC1 and non-small cell lung carcinoma: An investigation into the potential mechanisms responsible for the anticancer effects of the co-administration of Cur and cisplatin demonstrated that combined utilization sensitizes cisplatin resistance cells to cisplatin and synergistically inhibits the proliferation of NSCLC by inactivating the ERK pathway with the subsequent suppression of ERCC1 and thymidine phosphorylase (TP) expression [80].